Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan Daniel Schoenfeld, M.D.

Concepts (338)

Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Jonathan Schoenfeld's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Jonathan Schoenfeld has written about over time.
Radiotherapy, Intensity-Modulated, 8 publications between 2010 and 2022, average publication date December 2015. Carcinoma, Adenoid Cystic, 5 publications between 2010 and 2021, average publication date January 2018. Radiotherapy, 7 publications between 2015 and 2023, average publication date June 2018. Neoplasms, 23 publications between 2010 and 2024, average publication date July 2018. Neoplasm Recurrence, Local, 18 publications between 2013 and 2022, average publication date February 2019. Immunotherapy, 19 publications between 2011 and 2024, average publication date February 2019. Carcinoma, Squamous Cell, 20 publications between 2015 and 2024, average publication date February 2019. Oropharyngeal Neoplasms, 9 publications between 2015 and 2023, average publication date July 2019. Head and Neck Neoplasms, 33 publications between 2012 and 2024, average publication date September 2019. Combined Modality Therapy, 17 publications between 2016 and 2024, average publication date April 2020. Papillomavirus Infections, 9 publications between 2015 and 2023, average publication date May 2020.

To see the data from this visualization as text, click here.
Schoenfeld's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (338)
Explore
_
Co-Authors (159)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.